clinical trial · NCT07479797
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Kite, A Gilead Company·phase3·recruiting·n = 550
Relapsed or Refractory Large B-cell LymphomaKITE-753Axicabtagene CiloleucelFludarabineCyclophosphamide
brief summary
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.
started
Aug 1, 2026
primary completion
May 1, 2031
completion
May 1, 2031
last updated
May 12, 2026
official title
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol